DICHIARA, MARIA
 Distribuzione geografica
Continente #
NA - Nord America 1.358
EU - Europa 1.265
AS - Asia 527
AF - Africa 161
SA - Sud America 111
OC - Oceania 6
Totale 3.428
Nazione #
US - Stati Uniti d'America 1.328
IT - Italia 652
SG - Singapore 298
DE - Germania 217
CN - Cina 156
IE - Irlanda 133
CI - Costa d'Avorio 120
FI - Finlandia 105
BR - Brasile 104
RU - Federazione Russa 37
SN - Senegal 33
CA - Canada 26
ES - Italia 23
UA - Ucraina 19
GB - Regno Unito 15
KR - Corea 14
FR - Francia 13
VN - Vietnam 10
CZ - Repubblica Ceca 9
JP - Giappone 9
NL - Olanda 9
BD - Bangladesh 8
IN - India 8
SE - Svezia 7
PL - Polonia 6
BE - Belgio 5
TR - Turchia 5
AU - Australia 4
GR - Grecia 4
IQ - Iraq 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
CH - Svizzera 3
EC - Ecuador 3
HU - Ungheria 3
AR - Argentina 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
IL - Israele 2
MA - Marocco 2
MX - Messico 2
NZ - Nuova Zelanda 2
ZA - Sudafrica 2
CL - Cile 1
EG - Egitto 1
HK - Hong Kong 1
JO - Giordania 1
KZ - Kazakistan 1
LB - Libano 1
ME - Montenegro 1
NP - Nepal 1
PE - Perù 1
PS - Palestinian Territory 1
RO - Romania 1
TN - Tunisia 1
Totale 3.428
Città #
Chandler 295
Santa Clara 272
Munich 186
Singapore 183
Catania 152
Chicago 140
Dublin 132
Abidjan 120
Helsinki 79
Ashburn 60
Civitanova Marche 60
Boardman 54
Naples 38
Cambridge 33
Dakar 33
Lawrence 33
Andover 31
Nanjing 28
Hefei 24
Bremen 21
Des Moines 21
Toronto 18
Milan 17
Council Bluffs 16
Jacksonville 16
Rome 15
Palermo 14
Seoul 14
The Dalles 13
Columbus 12
Houston 12
Jyväskylä 12
Messina 11
Beijing 10
Centro 10
Madrid 10
Tokyo 9
Brno 8
Los Angeles 8
Sala Baganza 8
São Paulo 8
Cagliari 7
Florence 7
Hebei 7
Phoenix 7
Pozzallo 7
Shenyang 7
Wilmington 7
Bari 6
Changsha 6
Lappeenranta 6
Moscow 6
Nanchang 6
Saint Petersburg 6
Scafati 6
Terrassa 6
Belo Horizonte 5
Brussels 5
Civitavecchia 5
Dong Ket 5
Groningen 5
New York 5
Raffadali 5
San Francisco 5
Aci Catena 4
Curitiba 4
Guangzhou 4
Jiaxing 4
Marseille 4
Mascalucia 4
Pozzo Di Gotto 4
San Giovanni la Punta 4
Santa Maria di Licodia 4
Santiago de Compostela 4
Warsaw 4
Augusta 3
Bologna 3
Budapest 3
Castelvetrano 3
Dallas 3
Dearborn 3
Gravina di Catania 3
Hanoi 3
Kunming 3
London 3
Misterbianco 3
New Haven 3
Ottawa 3
Porto San Giorgio 3
Randazzo 3
Redwood City 3
Reggio Calabria 3
Rimini 3
Rio de Janeiro 3
Salerno 3
Tashkent 3
Tianjin 3
Turku 3
Villamagna 3
Washington 3
Totale 2.492
Nome #
Comprehensive data on a 2D-QSAR model for Heme Oxygenase isoform 1 inhibitors 218
Composti inorganici [Cap. 6] 201
Design, synthesis, and pharmacological evaluation of NO donor-sigma receptors hybrids for the treatment of cancer 128
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 111
Combination of heme oxygenase-1 inhibition and sigma receptor modulation for anticancer activity 107
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 104
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 99
Sigma-2 receptor ligands QSAR model dataset 92
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 91
Development of Sigma Receptors Nitric Oxide Photodonor Ligands with Antiproliferative Activity 90
La modellistica molecolare applicata ai recettori Sigma-1 e Sigma-2: un excursus 88
(+)-Methyl (1R,2S)-2-{[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropanecarboxylate [(+)-MR200] Derivatives as Potent and Selective Sigma Receptor Ligands: Stereochemistry and Pharmacological Properties 87
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 87
Heme Oxygenase Database (HemeOxDB) and QSAR Analysis of Isoform 1 Inhibitors 86
Hyphenated 3D-QSAR statistical model-scaffold hopping analysis for the identification of potentially potent and selective sigma-2 receptor ligands 85
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 83
Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review 81
New selective Sigma-1/HDACi prodrugs for neurodegenerative disorders 77
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 77
Tumor Targeting Sigma Receptor Ligands: Development of New Molecular Hybrids as Anticancer Therapeutics 76
CNS permeability parameters determination through a statistical analysis driven approach 76
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 74
Morphing of ibogaine: A successful attempt into the search for sigma-2 receptor ligands 71
Cytotoxicity Profiles and Neuroprotective Properties of the Novel Ifenprodil Analogues as Sigma Ligands 70
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 70
Novel Sigma Receptors Ligands-Nitric Oxide Photodonor: Molecular Hybrids for Double-Targeted Antiproliferative Effect 68
Design, Synthesis, and Cytotoxic Assessment of New Haloperidol Analogues as Potential Anticancer Compounds Targeting Sigma Receptors 67
Targeting the hydrophobic heme oxygenase-1 western region for the identification of novel and selective azole-based inhibitors. 67
Development of novel H2S-donor sigma receptor hybrids for the management of pain. 67
Identification of Potentially Potent Heme Oxygenase 1 Inhibitors through 3D-QSAR Coupled to Scaffold-Hopping Analysis 67
Development of NO-releasing sigma receptor hybrids as anticancer agents 66
Sigma Receptor Ligands Carrying a Nitric Oxide Donor Nitrate Moiety: Synthesis, In Silico, and Biological Evaluation 65
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 60
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 59
Recent advances in drug discovery of phototherapeutic non-porphyrinic anticancer agents 56
Repurposing of human kinase inhibitors in neglected protozoan diseases 54
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 53
Synthesis and evaluation of haloperidol metabolite II prodrugs as anticancer agents 52
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands 50
Exploring Structural Requirements for Sigma-1 Receptor Linear Ligands: Experimental and Computational Approaches 49
H2S releasing molecules in pharmaceutical development 42
Correction to Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 41
Structural and Molecular Insight into Piperazine and Piperidine Derivatives as Histamine H3 and Sigma-1 Receptor Antagonists with Promising Antinociceptive Properties 40
Discovery and computational studies of piperidine/piperazine-based compounds endowed with sigma receptor affinity 39
Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity 37
Dual Piperidine-Based Histamine H3 and Sigma-1 Receptor Ligands in the Treatment of Nociceptive and Neuropathic Pain 31
Sintesi e valutazione preclinica di ligandi per i recettori sigma utili per il trattamento dei tumori e per la gestione del dolore 29
Design and Synthesis of Tetrahydropyrrolo[3,4‐c]Pyrazole Sigma‐1 Receptor Ligands 23
Development of selective sigma-1 receptor ligands with antiallodynic activity: A focus on piperidine and piperazine scaffolds 9
Totale 3.620
Categoria #
all - tutte 12.645
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.645


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021145 5 1 14 34 44 2 15 1 5 0 10 14
2021/2022320 19 39 26 15 47 4 42 8 23 16 4 77
2022/2023745 69 66 15 107 49 116 8 123 143 9 34 6
2023/2024435 21 58 17 19 37 133 21 19 1 8 70 31
2024/20251.602 55 214 56 125 221 200 201 105 163 82 92 88
2025/202660 60 0 0 0 0 0 0 0 0 0 0 0
Totale 3.620